FIELD: medicine; oncology.
SUBSTANCE: invention can be used in treating oncological diseases in experiment. Method involves introducing into the body an exogenous environmentally friendly aqueous solution of hydrogen peroxide (hereinafter—ecoperoxide) in the concentration range from 500 to 850 mcM, which is introduced inside the body as an independent palliative agent, and in combination with other anticancer methods of treatment. Ecoperoxide is introduced intravenously or orally, as well as in a combination with resveratrol supplied to the body with food or in the form of a food additive.
EFFECT: use of the invention enables to achieve an anti-tumor effect by increasing oxygenation and oxidative potential of both the body and the tumor microenvelopment under the action of ecoperoxide, reducing the toxic load on the body both from the disease itself and from the anticancer therapy.
4 cl, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVE OF THE CLASS OF N-GLYCOSIDES INDOLO[2,3-A]PYRROLO[3,4-C]CARBAZOLE-5,7-DIONE - N-{12-(β-D-XYLOPYRANOSYL)-5,7-DIOXO-INDOLO[2,3-A]PYRROLO[3,4-C]CARBAZOL-6-YL} PYRIDINE-2-CARBOXAMIDE, WHICH HAS CYTOTOXIC AND ANTITUMOR ACTIVITY | 2017 |
|
RU2667906C1 |
| TITANIUM IMPLANT WITH THE FUNCTION OF LOCAL IMMUNOTHERAPY FOR OSTEORECONSTRUCTIVE SURGERY AND PREVENTION OF LOCAL RECURRENCE OF ONCOLOGICAL DISEASE AND METHOD FOR ITS MANUFACTURE | 2021 |
|
RU2779367C1 |
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| BIOMEDICAL CELL PRODUCT WITH ANTI-HER2 SPECIFIC ANTI-TUMOUR ACTIVITY | 2019 |
|
RU2728361C1 |
| LOW-TOXICITY PHARMACEUTICAL COMPOSITION WITH ANTICANCER ACTIVITY AGAINST CHOLANGIOCARCINOMA | 2023 |
|
RU2825942C1 |
| BIODEGRADABLE IMPLANT FOR LOCAL IMMUNOTHERAPY OF CANCER PATIENTS | 2021 |
|
RU2780932C1 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| BIODEGRADABLE METAL IMPLANT FOR LOCAL IMMUNOTHERAPY OF PATIENTS WITH SOLID TUMORS | 2021 |
|
RU2780927C1 |
| METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 |
|
RU2665168C1 |
| ANTITUMOUR AGENT | 2014 |
|
RU2572691C1 |
